PipelineReview.com1d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody ...
PipelineReview.com1d
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
PARIS, France and TARRYTOWN, NY, USA I 6, 2024 I The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis ...
PipelineReview.com1d
Hanmi Unveils Novel Obesity Drug ‘HM17321’ : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss
SEOUL, South Korea I November 6, 2024 I Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss ...
PipelineReview.com3d
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
November 04, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
PipelineReview.com3d
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...
PipelineReview.com3d
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
PASADENA, CA, USA I November 04, 2024 I Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the ...
PipelineReview.com3d
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
CARLSBAD, CA, USA I 4, 2024 I Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has ...
PipelineReview.com3d
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
SHANGHAI, China and CLINTON, NJ, USA I 4, 2024 I HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that ...
PipelineReview.com3d
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary Fibrosis SOUTH SAN ...
PipelineReview.com3d
Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes
The Phase 2 study will evaluate the efficacy, safety and tolerability of the company’s lead lipidated IL-22 analogue, CK-0045, in patients with obesity and type 2 diabetes COPENHAGEN, Denmark I ...